GCM
PACB icon

Glenview Capital Management’s Pacific Biosciences PACB Stock Holding History

Glenview Capital Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3,153,150
Closed -$10.9M – 49
2020
Q2 		$10.9M Sell
3,153,150
-75,345
-2% -$257K 0.3% 38
2020
Q1 		$9.88M Sell
3,228,495
-581,154
-15% -$2.38M 0.27% 37
2019
Q4 		$19.6M Buy
+3,809,649
New +$19.4M 0.17% 49

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Glenview Capital Management's PACB Position: Q3 2020 in Review

Glenview Capital Management sold out of Pacific Biosciences (PACB) in Q3 2020, closing a stake of 3,153,150 shares — an estimated $10.9M sold.

Glenview Capital Management first reported a position in PACB in Q4 2019 and held it in 3 quarters. The position peaked at $19.6M in Q4 2019. 174 funds tracked by Wall St. Rank hold PACB as of Q3 2020.

  • Glenview Capital Management reported no remaining Pacific Biosciences position as of Q3 2020 after selling out during the quarter.
  • Glenview Capital Management sold 3,153,150 Pacific Biosciences shares in Q3 2020, an estimated $10.9M.
  • Glenview Capital Management first reported a position in Pacific Biosciences in Q4 2019 and held it in 3 quarters.
  • Glenview Capital Management's Pacific Biosciences position peaked at $19.6M in Q4 2019.
  • 174 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2020.

Based on Glenview Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.